activity
20162023
most citedMUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials

16 citations · 72 across the 18 of their papers we have counts for

collaborators
Showing stat.MEShow all

12 papers · 1 filter

stat.ME2021★ 7 cited

On Bayesian Sequential Clinical Trial Designs

Tianjian Zhou, Yuan Ji

Clinical trials usually involve sequential patient entry. When designing a clinical trial, it is often desirable to include a provision for interim analyses of accumulating data wi…

stat.ME2021

A Unified Decision Framework for Phase I Dose-Finding Designs

Yunshan Duan, Shijie Yuan, Yuan Ji +1

The purpose of a phase I dose-finding clinical trial is to investigate the toxicity profiles of various doses for a new drug and identify the maximum tolerated dose. Over the past…

stat.ME2021★ 1 cited

Incorporating External Data into the Analysis of Clinical Trials via Bayesian Additive Regression Trees

Tianjian Zhou, Yuan Ji

Most clinical trials involve the comparison of a new treatment to a control arm (e.g., the standard of care) and the estimation of a treatment effect. External data, including hist…

stat.ME2021★ 2 cited

BaySize: Bayesian Sample Size Planning for Phase I Dose-Finding Trials

Xiaolei Lin, Jiaying Lyu, Shijie Yuan +2

We propose BaySize, a sample size calculator for phase I clinical trials using Bayesian models. BaySize applies the concept of effect size in dose finding, assuming the MTD is defi…

stat.ME2021★ 3 cited

PoD-BIN: A Probability of Decision Bayesian Interval Design for Time-to-Event Dose-Finding Trials with Multiple Toxicity Grades

Meizi Liu, Yuan Ji, Ji Lin

We consider a Bayesian framework based on "probability of decision" for dose-finding trial designs. The proposed PoD-BIN design evaluates the posterior predictive probabilities of…

stat.ME2020★ 1 cited

Hi3+3: A Model-Assisted Dose-Finding Design Borrowing Historical Data

Yunshan Duan, Sue-Jane Wang, Yuan Ji

Background -- In phase I clinical trials, historical data may be available through multi-regional programs, reformulation of the same drug, or previous trials for a drug under the…

stat.ME2020★ 4 cited

Semiparametric Bayesian Inference for the Transmission Dynamics of COVID-19 with a State-Space Model

Tianjian Zhou, Yuan Ji

The outbreak of Coronavirus Disease 2019 (COVID-19) is an ongoing pandemic affecting over 200 countries and regions. Inference about the transmission dynamics of COVID-19 can provi…

stat.ME2020★ 16 cited

MUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials

Jiaying Lyu, Tianjian Zhou, Shijie Yuan +2

We propose a multiple cohort expansion (MUCE) approach as a design or analysis method for phase 1b multiple expansion cohort trials, which are novel first-in-human studies conducte…

stat.ME2020★ 1 cited

Statistical Frameworks for Oncology Dose-Finding Designs with Late-Onset Toxicities: A Review

Tianjian Zhou, Yuan Ji

In oncology dose-finding trials, due to staggered enrollment, it might be desirable to make dose-assignment decisions in real-time in the presence of pending toxicity outcomes, for…

stat.ME2019

The i3+3 Design for Phase I Clinical Trials

Meizi Liu, Sue-Jane Wang, Yuan Ji

Purpose: The 3+3 design has been shown to be less likely to achieve the objectives of phase I dose-finding trials when compared with more advanced model-based designs. One major cr…

stat.ME2017★ 5 cited

On the Interval-Based Dose-Finding Designs

Yuan Ji, Shengjie Yang

The landscape of dose-finding designs for phase I clinical trials is rapidly shifting in the recent years, noticeably marked by the emergence of interval-based designs. We categori…

stat.ME2016★ 3 cited

A Bayesian Interval Dose-Finding Design Addressing Ockham's Razor: mTPI-2

Wentian Guo, Sue-Jane Wang, Shengjie Yang +2

There has been an increasing interest in using interval-based Bayesian designs for dose finding, one of which is the modified toxicity probability interval (mTPI) method. We show t…